Monday October 13, 6:00 am ET FDA confirms appropriateness of durable pain palliation as a primary endpoint for product marketing approval Milestone achievement results in release of escrowed shares BOTHELL, WA and VANCOUVER, Oct. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI - News ) today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC). In addition, OncoGenex reported that the FDA provided guidance on the submitted protocol including recommendations on study endpoints, the appropriate patient population, entry criteria and study...
[read full story]
Your Web Site
